SLC
VRTX icon

Second Line Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Second Line Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$559K Sell
1,125
-64
-5% -$28.4K 0.1% 77
2026
Q1 		$508K Buy
1,189
+45
+4% +$21K 0.1% 86
2025
Q4 		$519K Buy
1,144
+29
+3% +$12.5K 0.11% 74
2025
Q3 		$437K Buy
+1,115
New +$466K 0.09% 85

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Second Line Capital's VRTX Position: Q2 2026 in Review

Second Line Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 5.4% in Q2 2026, selling an estimated $28.4K and leaving 1,125 shares worth $559K. The position accounts for 0.1% of the portfolio, ranked #77.

Second Line Capital first reported a position in VRTX in Q3 2025 and has held it in 4 quarters since. 1,756 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Second Line Capital held 1,125 shares of Vertex Pharmaceuticals worth $559K as of Q2 2026.
  • Second Line Capital sold 64 Vertex Pharmaceuticals shares in Q2 2026, an estimated $28.4K.
  • Vertex Pharmaceuticals made up 0.1% of Second Line Capital's portfolio in Q2 2026, its #77 holding.
  • Second Line Capital first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 1,756 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Second Line Capital's 13F filing for Q2 2026, filed 12 Aug 2026.